Related Experiment Video
Updated: May 23, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about?
Vadim Tchaikovski1, Gregory Y H Lip
1Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, Birmingham, B18 7QH, England, UK.
Abstract:
The possibility of carcinogenic side effects of antihypertensive therapies due to their chronic administration has been raised multiple times in the past. Recently, the issue has again drawn attention, this time in relation to angiotensin receptor blockers (ARBs). This, among others, caused both American and European drug regulation authorities to review the underlying evidence concerning the relationship between this class of medications and potential adverse carcinogenic outcome. A plethora of both basic science and preclinical evidence has been generated, and three meta-analyses and one nationwide cohort have focused on this specific question. The current review aims to summarize the contemporary multidisciplinary evidence on whether ARBs may be associated with an increased risk of tumorigenesis.
Insights
Concerns about cancer risks with antihypertensive drugs, specifically angiotensin receptor blockers (ARBs), have resurfaced. This review synthesizes current evidence to assess if ARBs increase cancer risk.
Area of Science:
- Pharmacology and Oncology
- Cardiovascular Drug Safety
Background:
- Antihypertensive therapies, particularly angiotensin receptor blockers (ARBs), have faced scrutiny regarding potential carcinogenic side effects.
- Regulatory bodies in the US and Europe have re-examined evidence linking ARBs to cancer risk.
Purpose of the Study:
- To comprehensively review and synthesize current multidisciplinary evidence on the association between ARBs and tumorigenesis.
- To address the ongoing debate regarding the safety of ARBs concerning cancer development.
Main Methods:
- Review of existing scientific literature, including basic science and preclinical studies.
- Analysis of data from three meta-analyses and one nationwide cohort study.
- Synthesis of contemporary, multidisciplinary evidence.
Main Results:
- Evidence from basic science, preclinical studies, meta-analyses, and cohort studies was evaluated.
- The review consolidates findings to assess the link between ARBs and cancer risk.
- Contemporary data is summarized to inform the ongoing safety discussion.
Conclusions:
- The review provides a summary of current evidence regarding ARBs and cancer risk.
- It aims to clarify the association between this class of antihypertensive medications and potential tumorigenesis.
- Findings will contribute to the ongoing assessment of ARB safety by regulatory agencies and clinicians.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Mutagenicity and Carcinogenicity
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

